May 16, 2019—Siemens Healthineers announced the worldwide availability of its Atellica CH Enzymatic Hemoglobin A1c (A1c_E) Assay to assist clinicians in diagnosing and monitoring diabetes.
“Laboratories are seeking HbA1c assays that can be integrated onto chemistry testing platforms and that provide the accurate and precise results patients deserve,” Deepak Nath, PhD, president of laboratory diagnostics, Siemens Healthineers, said in a press release. “The new Atellica CH Enzymatic Hemoglobin A1c Assay offers these capabilities.”
Siemens offers HbA1c assays for diabetes testing on its clinical laboratory and point-of-care solutions, including the Atellica CH Analyzer, Advia chemistry systems, Dimension systems, Dimension Vista systems, and the DCA Vantage Analyzer.